Overview

Cardiac Safety of Indacaterol

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study compares the cardiac safety of inhaled indacaterol with that of placebo and oral moxifloxacin.
Phase:
Phase 1
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Fluoroquinolones
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination